🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Myriad Genetics, Inc. MYGN R2KR3KPHARMA

Healthcare · Diagnostics & Research · United States
https://www.myriad.com
Company Profile ↓
$5.82
-0.85% 1Y
Mkt Cap$556.68M
P/E-4.93
P/B1.22
52W High$8.18
52W Low$2.86
Book Value$3.18
EPS (TTM)$-1.18

Company Overview

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $824.50M (-1.6% YoY); net profit $-365.90M.
  • Trailing 12 Months Year-on-year growth — revenue -10.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 5.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:5.60%
1 Year:-10.50%

Stock Price Performance

1 Year:-0.85%
6 Months:+21.76%
3 Months:+6.79%
1 Month:+40.58%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 56% of range
$2.86 $8.18
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)74.78 · Overbought
Price Performance
1M+40.58%
3M+6.79%
6M+21.76%
1Y-0.85%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • Trading 28.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-4.93
Industry PE
25.45
Forward P/E
-10.15
PEG Ratio
1.24
Book Value
$3.18
Price to Book
1.22
P/S
0.46
EV/EBITDA
-12.19
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
5.60%
Profit 5Y
-
Revenue (YoY)
-10.50%
Earnings (YoY)
-

Profitability & Returns

ROCE
-67.60%
ROE
-32.54%
ROA
-8.60%
Profit Margin
-13.96%
Op Margin
-20.40%
Gross Margin
68.83%
EPS (Latest Qtr)
$-0.46
EPS (TTM)
$-1.18

Balance Sheet & Liquidity

Debt/Equity
0.69
Quick Ratio
1.72
Current Ratio
2.21
Debt
$210.50M
Total Assets
$638.90M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
4.01%
Chg in Prom Hold
-0.05%
FII / Inst Holding
97.09%
Chg in FII Hold
-0.02%

Financial Snapshot

Enterprise Value
$556.68M
Total Revenue (TTM)
$806.60M
EBITDA
$-40.30M
Free Cash Flow
$18.19M
Operating Cash Flow
$7.70M
Shares Outstanding
95.65M
Gross Margin
68.83%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MYGN Myriad Genetics, Inc. R2KR3KPHARMA 5.82 -4.93 $556.68M 0.00% -67.60% -32.54% 5.60% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2014Dec 2014Mar 2015Sep 2015Dec 2015Mar 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue ------178.90M196.70M194.70M199.60M178.80M187.90M183.10M193.90M202.30M216.80M216.60M215.40M186.30M195.10M164.00M93.20M145.20M173.10M189.40M167.30M164.90M179.30M156.40M181.20M183.50M191.90M202.20M211.50M213.30M195.90M213.10M205.70M200.40M190.70M
Gross Profit --------------------------------137.60M147.10M149.80M134.20M151.80M143.80M137.60M127.00M
Operating Income 25.90M36.30M35.70M43.30M45.20M42.60M7.10M17.20M5.50M18.90M84.00M6.30M13.80M17.80M1.20M6.10M5.90M-5.60M-20.90M-8.80M-133.70M-68.30M-39.60M-46.70M-20.80M-79.90M-25.60M-17.80M-45.00M-52.20M-113.70M-60.10M-27.90M-36.50M-20.00M-29.00M-329.20M-23.30M-30.70M-38.90M
Net Income 16.00M24.00M21.40M30.30M37.10M34.50M-700.00K6.10M2.80M12.30M78.80M30.90M9.10M14.50M-700.00K2.60M6.90M-4.20M-20.60M-8.30M-115.20M-55.40M-15.20M-39.50M-4.70M24.60M-20.50M-14.10M-35.10M-54.70M-116.10M-61.30M-26.00M-36.70M-22.10M-100.00K-330.50M-27.40M-34.10M-43.20M
Diluted EPS 0.210.320.290.420.500.47-0.010.090.040.181.120.430.130.20-0.010.030.09-0.06-0.28-0.11-1.55-0.74-0.20-0.52-0.060.30-0.26-0.18-0.43-0.67-1.42-0.75-0.29-0.41-0.240.00-3.57-0.29-0.36-0.46
R&D Expense 22.60M17.50M16.70M17.20M16.70M17.20M19.40M18.60M17.60M18.80M17.80M16.80M18.50M17.70M21.10M22.40M21.50M20.90M21.30M18.80M19.70M17.40M17.60M23.10M19.50M18.80M21.20M20.30M20.50M22.50M21.20M24.00M24.90M27.10M28.50M27.50M25.60M28.20M27.10M25.00M

Profit & Loss (Annual)

Figures in USD.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 326.53M362.65M402.08M496.00M613.20M778.20M722.50M740.50M728.70M743.70M851.10M638.60M557.10M690.60M678.40M753.20M837.60M824.50M
Gross Profit --------------476.40M517.00M585.40M576.60M
Operating Income 126.46M135.07M157.78M180.32M228.00M274.40M133.60M153.40M44.00M121.90M7.60M-231.70M-289.70M-190.50M-140.60M-257.40M-123.50M-387.20M
Net Income 84.61M152.30M100.71M112.15M147.20M176.20M79.80M117.20M17.40M133.30M4.60M-199.50M-223.60M-27.20M-112.00M-263.30M-127.30M-365.90M
Diluted EPS 0.861.541.101.301.772.251.071.600.251.850.06-2.69-2.99-0.35-1.39-3.18-1.41-3.95
R&D Expense 17.91M21.87M27.75M42.65M53.70M67.50M75.50M70.60M74.40M70.80M85.90M77.20M73.30M81.90M85.40M88.70M113.40M106.80M

Balance Sheet (Annual)

Figures in USD.

Metric Jun 2008Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --593.85M610.83M690.63M803.82M823.80M766.20M880.50M1.21B1.18B1.56B1.40B1.42B1.32B1.20B1.15B1.03B706.60M
Total Equity 425.65M434.22M557.58M566.79M635.80M728.60M719.00M661.70M739.60M768.40M966.10M1.09B918.20M881.00M967.80M885.80M783.20M701.10M368.00M
Cash & Equivalents 237.73M63.51M92.84M52.68M86.40M104.10M64.80M64.10M68.50M102.40M110.90M93.20M163.70M117.00M257.40M56.90M132.10M102.40M149.60M
Long Term Debt ---------99.10M9.30M233.50M224.40M224.80M0038.50M39.60M119.90M
Total Liabilities --36.27M44.03M54.98M75.23M104.80M104.10M132.40M440.90M209.20M473.80M486.40M537.80M352.90M312.90M363.30M326.50M338.60M
Current Liabilities --27.47M34.39M44.97M64.51M80.60M68.70M72.30M217.50M102.20M117.80M147.00M145.90M204.30M137.20M155.90M164.10M133.80M

Cash Flows (Annual)

Figures in USD.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 84.04M155.09M130.83M141.80M173.87M--166.30M106.20M115.90M83.70M60.70M--106.30M-110.90M-8.70M1.80M
Investing Cash Flow -206.34M-76.67M-54.39M-38.89M-75.59M---91.40M-146.30M-11.60M-286.40M19.30M--77.50M31.90M-11.90M-27.40M
Financing Cash Flow -51.92M-49.09M-116.60M-69.25M-80.56M---68.30M71.80M-95.00M182.30M-10.00M--8.00M152.90M-7.40M64.20M
Capital Expenditure --------------45.30M-73.30M-29.70M-27.40M
Free Cash Flow --------------151.60M-184.20M-38.40M-25.60M
Net Change in Cash --------------191.80M73.90M-28.00M38.60M
Share Buybacks -71.39M200.49M128.47M146.30M287.70M210.70M162.60M31.60M-50.00M00----

Ratios (Annual)

Figures in %.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------70.2%68.6%69.9%69.9%
Operating Margin % 38.7%37.2%39.2%36.4%37.2%35.3%18.5%20.7%6.0%16.4%0.9%-36.3%-52.0%-27.6%-20.7%-34.2%-14.7%-47.0%
Net Margin % 25.9%42.0%25.0%22.6%24.0%22.6%11.0%15.8%2.4%17.9%0.5%-31.2%-40.1%-3.9%-16.5%-35.0%-15.2%-44.4%
ROE % 19.5%27.3%17.8%17.6%20.2%24.5%12.1%15.8%2.3%13.8%0.4%-21.7%-25.4%-2.8%-12.6%-33.6%-18.2%-99.4%
ROCE % -23.8%27.4%27.9%30.8%36.9%19.2%19.0%4.4%11.4%0.5%-18.4%-22.8%-17.1%-13.2%-26.0%-14.3%-67.6%

Shareholding Pattern

Insiders
4.01%
Institutions
97.09%
Public Float
101.14%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 11.39% 10.89M $46.94M
2 Millennium Management Llc 6.92% 6.62M $28.53M
3 Vestal Point Capital, LP 6.00% 5.74M $24.72M
4 State Street Corporation 5.21% 4.99M $21.49M
5 Shaw D.E. & Co., Inc. 4.79% 4.58M $19.75M
6 Vanguard Capital Management LLC 4.27% 4.08M $17.59M
7 Acadian Asset Management. LLC 3.27% 3.13M $13.48M
8 Vanguard Portfolio Management LLC 3.22% 3.08M $13.27M
9 AQR Capital Management, LLC 2.89% 2.77M $11.92M
10 Morgan Stanley 2.59% 2.48M $10.69M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MYGN

Google News hu, 22 Oct 2026

Myriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst Revisions - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOR0ZBSE5oNWRWcS1oNGo3eXA4VUhPYlpONG9FSHd2c0dPYkE4dmxQYm1pdTItVlRRczhDQWdJdDNlcF9xcDdnWlRYNzhyNE9OUFZBOVlHVmZvSVhHdHljc2JITG81Q2JyMGp3LUhGaHJ2SElld1BYTWpiLWlJTWJuRG02aHBuTFhUUU1sel…

Google News ue, 20 Oct 2026

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - TradingView

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPNkxtdzM2a3BSYXFnTElWZWtwWWJ5cXMxckdxV3lRZTBJVXBkdnZ4cWQ2dDFTel9HR1hFbFJzMWNTYjFBblhjMlZNSVdXMl9EcWQtc2ZlSFFpSFFRNVIyWDhxaks1TmR5UEsyVmMwMnJZSkIxX0lKVVZlcVR2emJITWRMcGdraTlKdEE5V0…

Google News Wed, 21 Oct 2026

Myriad Genetics (MYGN) Stock Forecast & Analyst Ratings - Moomoo

<a href="https://news.google.com/rss/articles/CBMi9AJBVV95cUxNMDhsNi1oWm9yMk5RbHh0YURBSTgyR2xEN2gzZU9hc2hOWE5tRGx6cTFDQ1U4WHFSZmduZWRfNjFXYzVYcklPdi1iNFpyYXRDMHphOERnN196VDZqWkZ6MFFfVVVfNE1KWVRaS1BjcDBObXRtXzJLYlRzeVFxU0VQWVZkUEZxaXAySFpDS3…

Google News Wed, 21 Oct 2026

Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance Singapore

<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE1XMzNMS1RHa2hxM01sTFZIX1pfTFdoXzluYnpkSmYwYTVUUTZ3dk8ydE1oLVFXNzRpRWh2V2FrQ1ZSWjdILUZMV1VoZklKTzM2ZVE?oc=5" target="_blank">Myriad Genetics, Inc. (MYGN) stock price, news, quote an…

Google News hu, 22 Oct 2026

Myriad Genetics: Prenatal Sale Provides A Lifeline In A Tough Spot (NASDAQ:MYGN) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNMUtyMmpyWHUzM1BUampDdmQwaVMxUmNacDIta3VlMFBSdnRESUNtUDJlR2hBM3BvNEJCTXd1UkVwaWpiakZBOW9LRncwTm5zdjFLVDRNSUNHVGxkWEk0OWI5UVJPYVNhUXNyWlRGVnlxQXdhSlpJOHR1VHF1aEtpbDM3WnlWbFp1eHRISX…

Google News ue, 20 Oct 2026

Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business - Investorideas.com

<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxOeF82b2tKeWY3WmYwNVY4aWg2NnV3X1JZV0h2Zk85RDBJNkZJYXR0dmxxSFgySElSUjluQVRRYl9PR21nZmZQc3JqQUlHOUdlaTcwaGM3RFE0VE5zbU9xY1oycXE5NzV6RHdnTFZRZ2EzTTdVRXE2blF0T0pLM2Q0YnFma3lyM2ZfeUFOdE…

MYGN — Frequently Asked Questions

What is the current share price of Myriad Genetics, Inc. (MYGN)?

As of 2026-10-23 16:27 PDT, Myriad Genetics, Inc. (MYGN) trades at $5.82 on NasdaqGS. Its 52-week range is $2.86 to $8.18.

What is the market capitalisation of MYGN?

Myriad Genetics, Inc. (MYGN) has a market capitalisation of $556.68M on NasdaqGS.

What is the P/E ratio of MYGN?

MYGN trades at a trailing price-to-earnings (P/E) ratio of -4.93. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.22.

What is the return on equity (ROE) of MYGN?

MYGN has a return on equity (ROE) of -32.54%. Its return on capital employed (ROCE) is -67.60%.

Is MYGN a good stock to buy?

This page provides a data-driven analysis of Myriad Genetics, Inc. (MYGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space